smaller steps here
Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.
🔥6
smaller steps here
#retatrutide 2026-05-24
Sunday61 messages13 participantstimes are UTC
Highlights from this day
- bea_reconstitutes — triple agonist, GLP-1 and GIP and glucagon. the glucagon arm is the part with no long history buying this is a completely different risk conversation from the… 16:10
- bea_reconstitutes — appetite suppression at 1.7 was stronger than my tirzepatide experience at a comparable point 16:58
- triumph_watch — nobody should read my log as a plan, im recording what i did and thats all it is 19:22
🔥6
Medutest came back 97.4 on one lot and 96.8 on the next from the same HJ, both fine
settled by month three
watching my heart rate
blood pressure stayed flat for me while heart rate moved, which i didnt expect, thats just me
📉5
stepping in 2.4 increments instead of doubling is the only thing i would change if i started again
TRIUMPH is the phase 3 programme, thats the name to search rather than the molecule
there is no long term safety data, phase 2 and an ongoing phase 3 programme is what exists
triple agonist yeah
is there any long term safety data at all or is it phase 2 and hope
💀6
why does everyone insist on smaller steps here than on the other two
anyone gone above 15 and what changed
my resting heart rate is up about 7 bpm, did that settle for anyone
mine went up too
the phase 2 weight result was larger than what the earlier agonists reported, in a smaller shorter trial, i think
Digest for the week of 2025-08-26 has been published.
for the archive buying this is a completely different risk conversation from the licensed compounds and that gets said too rarely
lost 25kg over 24 months at doses well under what the trials used
glucagon is the new bit
janoshik-kp-0925.pdf
2 pages · 270 KB · not retained in the public archive
👀4❤️6📈16
the purity spread across lots worries me more than the molecule does
energy expenditure isnt something i could feel, though my sleep tracker disagreed with me
⚠️1
research use only is on every vial and i treat it as exactly that, nobody here is prescribing
*that should say weekly
how do people square the research use only framing with logging their own use
did the phase 2 plateau or was it still moving at the end
is TRIUMPH the phase 3 programme
i went up too fast, got a fortnight of nothing but nausea, and dropped back two steps
15:41marrow.mod pinned a message
unrelated but the heart rate thing is real enough that i mention it whenever someone asks about starting, thats one data point
no long term data
held at 15 for 12 months and it never plateaued for me, which i cant explain
triple agonist, GLP-1 and GIP and glucagon. the glucagon arm is the part with no long history
buying this is a completely different risk conversation from the licensed compounds and that gets said too rarely
📈13🧪1✅2
did anyone come off because of the heart rate
genuine question GI was about the same as tirzepatide for me, the difference was how fast it arrived
i went up too fast, got a fortnight of nothing but nausea, and dropped back two steps
TRIUMPH is phase 3
baseline 58
wk 2 61
wk 4 64
wk 6 67
wk 8 66
wk 10 65 (held dose from wk 7)the glucagon arm is the mechanistic story for extra energy expenditure and its still a story to me
anyone stayed at 1 for months rather than climbing
phase 2 only
appetite suppression at 1.7 was stronger than my tirzepatide experience at a comparable point
📈17
low and slow here means smaller steps than i ever used on tirzepatide, thats the received wisdom
people insist on small steps because the side effects arrive faster than on the other two
*PeptideMeter not the other one
is the phase 2 dosing anywhere near what people here run
how long before people saw the first change at 2.5
👀4🎉10🤝1
17:28marrow.mod pinned a message
held mine ages
[edited]does the energy expenditure claim show up as anything you can feel
does the glucagon arm explain the heart rate or is that unrelated
is the GI worse than tirzepatide or about the same
🔥1📈3
triple agonist meaning GLP-1, GIP and glucagon, have i got that right
energy expenditure isnt something i could feel, though my sleep tracker disagreed with me
my resting rate went up 9 bpm in the first month and came back most of the way by month 23
is the glucagon arm what people mean by the energy expenditure thing
phase 2 was still trending at the end which is why the phase 3 readout matters more than usual
nobody should read my log as a plan, im recording what i did and thats all it is
😂12🔥14
cant feel it honestly
whats a sensible starting point, im seeing everything from 0.5 to 2
sat at 12 for 8 months rather than climbing and it kept working, so i never went up
the half life supports weekly dosing and thats what ive done from the start
research use only
coming back to this reconstituted the 2 vial to 4mg/ml specifically so i could take 7.5 without measuring crumbs
i log resting heart rate every morning because of this and its the one number i actually watch
*Medutest not the other one